<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>early intervention outcomes &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/early-intervention-outcomes/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 30 Sep 2025 08:31:12 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>early intervention outcomes &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Biologic Therapy Lowers Symptoms and Hospitalization Rates in Severe Pulmonary Hypertension Following Diagnosis</title>
		<link>https://bioengineer.org/biologic-therapy-lowers-symptoms-and-hospitalization-rates-in-severe-pulmonary-hypertension-following-diagnosis/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 30 Sep 2025 08:30:56 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[activin signaling antagonism]]></category>
		<category><![CDATA[early intervention outcomes]]></category>
		<category><![CDATA[HYPERION clinical trial]]></category>
		<category><![CDATA[pulmonary arterial hypertension treatment]]></category>
		<category><![CDATA[sotatercept therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/biologic-therapy-lowers-symptoms-and-hospitalization-rates-in-severe-pulmonary-hypertension-following-diagnosis/</guid>

					<description><![CDATA[Pulmonary arterial hypertension (PAH) is a progressive vascular disease characterized by elevated pressure in the pulmonary arteries, which ultimately leads to right heart failure and premature death. Despite advances in therapeutic approaches, PAH remains a condition with significant morbidity and mortality, often presenting at advanced stages. However, a pivotal new study published in the New [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">273623</post-id>	</item>
	</channel>
</rss>
